<DOC>
	<DOCNO>NCT00192062</DOCNO>
	<brief_summary>This Phase II study gemcitabine- Vinorelbine combination 3-weekly schedule first line chemotherapy patient metastatic breast cancer . Eighty patient measurable disease enrol study . Gemcitabine use 1000 mg/m2 , vinorelbine 25mg/m2 . Every cycle , vinorelbine administer gemcitabine . After initial dose , modification Gemcitabine vinorelbine dose allow base patient toxicity Study therapy may continue : - There evidence progressive disease - The patient experience unacceptable toxicity . - The investigator decide patient discontinue - The patient request discontinuation - The patient receive 6 cycle regimen ( physician decides continue 6 cycles-this do consultation sponsor ) - Discontinuation study therapy indicate accord protocol It 's investigator 's responsibility strictly stick protocol procedure . It need discuss Lilly medical designee advance special situation occurs define protocol . After patient discontinue study therapy , proceed post-study follow phase study . Assessments take place phase outline protocol .</brief_summary>
	<brief_title>A Trial Gemcitabine Combined With Vinorelbine First Line Chemotherapy Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Inclusion Criteria Histological cytological diagnosis breast carcinoma evidence unresectable , locally recurrent , metastatic disease . Lesions amenable surgery radiation curative intent . Presence metastatic localregional recurrent disease , accord American Joint Committee Cancer ( Greenz , et al , 2002 ) . Unidimensionally measurable lesion clearly define margin clearly measurable follow method accord computerized tomography ( CT ) , Chest xray clinical examination , accord RECIST criterion ( Therasse , et al , 2002 ) . No prior chemotherapy metastatic locoregionally recurrent disease . Prior adjuvant neoadjuvant chemotherapy Anthracyclines base regimen mandatory . The time last dose prior adjuvant chemotherapy study entry must least 30 day patient must completely recover acute chemotherapy relate toxicity ( exception alopecia ) . Prior radiotherapy must complete least 30 day study entry . No concurrent hormonal therapy MBC . Prior hormonal therapy allow , time last dose prior hormonal therapy breast cancer study enrollment must least 1 week . Exclusion Criteria Have receive treatment within last 30 day investigational drug indication study entry . Concurrent administration tumor therapy , include cytotoxic chemotherapy , surgery cancer , radiotherapy , hormonal therapy immunotherapy ( include Herceptin ) . Active infection opinion investigator would compromise patient 's ability tolerate therapy , unless adequately treat . Pregnancy breastfeed . Serious concomitant disorder would compromise safety patient compromise patient 's ability complete study , discretion investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>